Larynx carcinoma in situ

Summary

Larynx carcinoma in situ (MONDO:0004696) is a cancer and 2 clinical trials. A subtype of laryngeal carcinoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer
• Clinical trials: 2

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	larynx carcinoma in situ
Mondo ID	MONDO:0004696
DOID	DOID:9011
ICD-10-CM	D02.0
NCIT	C9100
SNOMED CT	92634009
UMLS	C0154069
MedGen	56336
GARD	0027702
Anatomy (UBERON)	UBERON:0001737
Is cancer (heuristic)	yes

Also known as: carcinoma in situ of larynx · carcinoma in situ of the larynx · laryngeal cancer stage 0 · laryngeal carcinoma in situ · laryngeal carcinoma stage 0 · larynx carcinoma in situ · larynx in situ carcinoma · stage 0 carcinoma of larynx · stage 0 carcinoma of the larynx · stage 0 laryngeal cancer · stage 0 laryngeal cancer aJCC v6 · stage 0 laryngeal cancer aJCC v6, v7, and V8 · stage 0 laryngeal cancer aJCC v7 · stage 0 laryngeal cancer aJCC v8 · stage 0 laryngeal carcinoma · stage 0 laryngeal carcinoma in situ · stage 0 laryngeal throat cancer · stage 0 larynx carcinoma

Disease family

This is a subtype of laryngeal carcinoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › respiratory system cancer › larynx cancer › laryngeal carcinoma › larynx carcinoma in situ

Related subtypes (7): glottis carcinoma, laryngeal mucoepidermoid carcinoma, carcinoma of supraglottis, subglottis carcinoma, laryngeal squamous cell carcinoma, laryngeal adenoid cystic carcinoma, laryngeal small cell carcinoma

Subtypes (1): carcinoma in situ of epiglottis

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 2.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE1/PHASE2	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01469429	PHASE1/PHASE2	COMPLETED	Phase 1b Food Based Modulation of Biomarkers in Human Tissues at High-Risk for Oral Cancer.
NCT01473784	Not specified	RECRUITING	Transoral Robotic Surgery in Treating Patients With Benign or Malignant Tumors of the Head and Neck